Roxadustat for CKD-related Anemia in Non-dialysis Patients

Area of Science:

• Nephrology
• Hematology
• Pharmacology

Background:

• Anemia is a common complication in patients with chronic kidney disease (CKD).
• Roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, offers a novel therapeutic approach by stimulating erythropoiesis and improving iron metabolism.
• This study focuses on the efficacy and tolerability of roxadustat in non-dialysis CKD patients with anemia.

Purpose of the Study:

• To evaluate the efficacy of roxadustat in correcting and maintaining hemoglobin levels in adults with stage 3-5 CKD not on dialysis.
• To assess the safety and tolerability profile of roxadustat compared to placebo in this patient population.

Main Methods:

• A global Phase 3 randomized controlled trial (ANDES study) involving adults with stage 3-5 CKD not on dialysis.
• Patients received either roxadustat or placebo, with initial thrice-weekly dosing and subsequent titration to achieve target hemoglobin levels.
• Primary efficacy endpoints included change in hemoglobin from weeks 28-52 and the proportion of patients achieving a hemoglobin response at week 24.

Main Results:

• Roxadustat demonstrated a significantly greater mean increase in hemoglobin over weeks 28-52 compared to placebo (1.85 g/dl difference, P < 0.0001).
• A substantially higher proportion of patients achieved the target hemoglobin response at week 24 with roxadustat (86.0%) versus placebo (6.6%, P < 0.0001).
• The incidence of treatment-emergent adverse events and serious adverse events was comparable between the roxadustat and placebo groups.

Conclusions:

• Roxadustat effectively corrects and maintains hemoglobin levels in patients with CKD-related anemia not on dialysis.
• The oral hypoxia-inducible factor prolyl hydroxylase inhibitor demonstrates a favorable tolerability profile in this patient group.
• The findings support roxadustat as a viable treatment option for anemia in non-dialysis CKD patients.